Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...